BioSig Technologies Inc said that its PURE EP System has exceeded its procedural target of 1,500 patient cases in 2021.
As of October 21, 2021, the PURE EP System had been used in over 1,560 patient cases by 71 physicians, up from 1,000 cases in June 2021, when the procedural guidance was raised amid increased technology usage in elective procedures.
As the adoption of the technology increases and the coronavirus (COVID-19) hospitalization rates continue to decline, the company said intends to complete between 1,700-1,800 procedures by the end of 2021.
“We are seeing increased utilization of PURE EP in the 13 hospitals we are currently working in. Physicians recognize value both clinically and economically or they would not be increasing their usage. Hospitals are rapidly scaling their elective procedures and thus we are now seeing increased case volumes and commercial activity,” Kenneth L. Londoner, Chairman and CEO of BioSig said in a statement.
READ: BioSig Technologies says its flagship technology to be featured in a live patient case streamed during the 16th Annual International Symposium on Ventricular Arrhythmia
The company noted that clinical data acquired by the PURE EP System in a multi-center study at Texas Cardiac Arrhythmia Institute at St David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library via the following link: https://onlinelibrary.wiley.com/doi/10.1111/jce.15250.
Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over conventional sources.
BioSig is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
PURE EP System, the company’s first product, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Contact the author at jon.hopkins@proactiveinvestors.com